Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 sq.-ft. facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of its pDNA service offering, which was recently acquired from Delphi Genetics to support cell and gene therapies.   The HCTS facility houses an existing cleanroom infras...